{
    "nctId": "NCT02691793",
    "officialTitle": "Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors",
    "inclusionCriteria": "* Provision of fully informed consent prior to study specific procedures.\n* Patients must be \\>= 19 years of age\n* RET fusion positive or FGFR2 fusion/other FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy.\n* ECOG Performance status0-2\n* Have measurable or evaluated disease based on RECIST 1.1 as determined by investigator.\n* Adequate Organ Function Laboratory values\n\n  * Absolute neutrophil count \\>= 1.5 x 109/L, Hemoglobin \\>= 9g/dL, Platelets\\>=100 x 109/L Bilirubin \\<= 1.5 x upper limit of normal AST/ALT \\<= 2.5 X upper limit of normal(5.0 x upper limit of normal, for subject with liver metastases) Creatinine\\<= 1.5 X UNL\n* Patients of child-bearing potential should be using adequate contraceptive measures should not be breast feeding and must have a negative pregnancy test prior to start of dosing\n* Adequate heart function\n* Must have minimum age of 19 Years",
    "exclusionCriteria": "* Patients with second primary cancer, except:adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumor curatively treated with no evidence of disease for \\<= 5 years.\n* Has known active central nervous system(CNS) metastases\n* Has an active infection requiring systemic therapy\n* Pregnancy or breast feeding\n* Patients with cardiac problem\n* Any previous treatment with sunitinib"
}